8/31/2015 - 11:53 AM EST - Resverlogix Corp. : Announced that Dr. Norman Wong, its chief scientific officer, presented new data at the European Society of Cardiology (ESC) Congress 2015 in a poster presentation titled: "RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-I/HDL." Resverlogix Corp.
shares T.RVX are trading down $0.02 at $1.55.